Biomerica, Inc. (BMRA) P/E Ratio History
Historical price-to-earnings valuation from 1995 to 2014
Loading P/E history...
BMRA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, Biomerica, Inc. (BMRA) trades at a price-to-earnings ratio of -1.0x, with a stock price of $2.22 and trailing twelve-month earnings per share of $-1.38.
The current P/E is 100% below its 5-year average of 263.5x. Over the past five years, BMRA's P/E has ranged from a low of 28.2x to a high of 3040.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 21.9x, BMRA trades at a 105% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, BMRA trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BMRA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BMRA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $17B | 30.5 | - | -25% | |
| $7B | 9.1Lowest | - | +143%Best | |
| $44B | 42.8 | 3.00Best | +23% | |
| $173B | 26.2 | 12.41 | +7% | |
| $121B | 34.0 | - | -5% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BMRA Historical P/E Data (1995–2014)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2014 Q1 | Sat Aug 31 2013 00:00:00 GM | $7.20 | $0.01 | 911.4x | +12% |
| FY2013 Q4 | Fri May 31 2013 00:00:00 GM | $7.12 | $0.07 | 100.4x | -88% |
| FY2013 Q3 | $9.20 | $0.07 | 127.2x | -84% | |
| FY2013 Q2 | Fri Nov 30 2012 00:00:00 GM | $6.72 | $0.11 | 62.6x | -92% |
| FY2013 Q1 | Fri Aug 31 2012 00:00:00 GM | $5.68 | $0.11 | 52.9x | -93% |
| FY2012 Q4 | $5.52 | $0.09 | 63.2x | -92% | |
| FY2012 Q3 | Wed Feb 29 2012 00:00:00 GM | $6.08 | $0.09 | 64.7x | -92% |
| FY2012 Q2 | Wed Nov 30 2011 00:00:00 GM | $3.84 | $0.07 | 51.9x | -94% |
| FY2012 Q1 | Wed Aug 31 2011 00:00:00 GM | $3.60 | $0.04 | 81.8x | -90% |
| FY2011 Q4 | $3.60 | $0.02 | 162.2x | -80% | |
| FY2010 Q2 | Mon Nov 30 2009 00:00:00 GM | $3.04 | $0.00 | 3040.0x | +274% |
| FY2010 Q1 | Mon Aug 31 2009 00:00:00 GM | $3.36 | $0.03 | 106.3x | -87% |
Average P/E for displayed period: 813.4x
See BMRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BMRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBMRA — Frequently Asked Questions
Quick answers to the most common questions about buying BMRA stock.
Is BMRA stock overvalued or undervalued?
BMRA trades at -1.0x P/E, below its 5-year average of 263.5x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does BMRA's valuation compare to peers?
Biomerica, Inc. P/E of -1.0x compares to sector median of 21.9x. The discount suggests lower growth expectations or higher risk.
What is BMRA's PEG ratio?
BMRA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1995-2014.